Pfizer's chief scientist Mikael Dolsten to step down
Adds background throughout, CEO quote in paragraph 5
July 9 (Reuters) -Pfizer PFE.N said on Tuesday Chief Scientific Officer Mikael Dolsten, a key figure behind the development of its COVID-19 vaccine, would step down after a more than 15-year career at the drugmaker.
Dolsten, aged 65, served as the head of Pfizer's research and development after he joined the company through its $68 billion acquisition of Wyeth in 2009. He became the company's chief scientist in 2010.
During his tenure, Comirnaty — jointly developed by Pfizer and BioNTech — became the first COVID vaccine to get an approval from the U.S. Food and Drug Administration in 2021, just 13 months after its trial began, in a record time to approval for any shot or therapeutic.
Pfizer also developed and launched multi-billion dollar products such as heart disease drug Vyndaqel and blood thinner Eliquis, after the company struggled to remain competitive with other drugmakers.
"After more than 15 years as the architect of Pfizer's exceptional scientific and research and development resurgence, Mikael and I recently discussed starting the process to look for his successor," said CEO Albert Bourla.
The company said its process to identify a successor is expected to last several months.
A new chief scientist would come at a time when billions of dollars in COVID vaccine and treatment sales have disappeared as pandemic worries ease.
The steep drop in COVID product sales had also forced Pfizer to launch a program to reduce expenses by about $1.5 billion by the end of 2027, adding on to a $4 billion cost-cutting plan it announced last year.
Reporting by Christy Santhosh in Bengaluru; Editing by Shilpi Majumdar
免責聲明: XM Group提供線上交易平台的登入和執行服務，允許個人查看和/或使用網站所提供的內容，但不進行任何更改或擴展其服務和訪問權限，並受以下條款與條例約束：（i）條款與條例；（ii）風險提示；（iii）完全免責聲明。網站內部所提供的所有資訊，僅限於一般資訊用途。請注意，我們所有的線上交易平台內容並不構成，也不被視為進入金融市場交易的邀約或邀請 。金融市場交易會對您的投資帶來重大風險。
所有缐上交易平台所發佈的資料，僅適用於教育/資訊類用途，不包含也不應被視爲適用於金融、投資稅或交易相關諮詢和建議，或是交易價格紀錄，或是任何金融商品或非應邀途徑的金融相關優惠的交易邀約或邀請。
本網站的所有XM和第三方所提供的内容，包括意見、新聞、研究、分析、價格其他資訊和第三方網站鏈接，皆爲‘按原狀’，並作爲一般市場評論所提供，而非投資建議。請理解和接受，所有被歸類為投資研究範圍的相關内容，並非爲了促進投資研究獨立性，而根據法律要求所編寫，而是被視爲符合營銷傳播相關法律與法規所編寫的内容。請確保您已詳讀並完全理解我們的非獨立投資研究提示和風險提示資訊，相關詳情請點擊 這裡查看。
